MicroRNA-211-5p Suppresses Tumour Cell Proliferation, Invasion, Migration and Metastasis in Triple-negative Breast Cancer by Directly Targeting SETBP1

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 Jun 2

PMID 28571042

Citations 67

Authors

Liang-Liang Chen

Zhou-Jing Zhang

Zhan-Bo Yi

Jian-Jun Li

Affiliations

Soon will be listed here.

Abstract

Background: Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancer in women globally. This subtype often has early and high recurrence rates, resulting in poor survival, partially due to lack of targeted therapies. To date, the detailed molecular mechanisms underlying TNBC progression are unclear. Given the crucial role of microRNAs (miRNAs) in cancer metastasis, we aimed to analyse the expression and function of a metastasis-associated miRNA named miR-211-5p in TNBC.

Methods: MiRNA array analysis was performed to search for metastasis-associated miRNAs in TNBC. The miR-211-5p expression in tumour tissues, adjacent non-tumourous breast tissues of TNBC patients and cell lines were evaluated by real-time PCR. The protein expression levels were analysed by western blot, immunohistochemistry and in situ hybridisation. Luciferase reporter assays were employed to validate the target of miR-211-5p. The effect of miR-211-5p on TNBC progression was investigated in vitro and in vivo.

Results: MiR-211-5p was significantly downregulated in TNBC, and its expression level was associated with overall survival in TNBC. The expression of miR-211-5p suppressed TNBC cell proliferation, invasion, migration and metastasis in vitro and in vivo. Furthermore, SETBP1 was identified as a target of miR-211-5p. Through gain-of-function and loss-of-function studies, SETBP1 was shown to significantly affect colony and cell number in vitro. Enforced expression of miR-211-5p inhibited the expression of SETBP1 significantly and the restoration of SETBP1 expression reversed the inhibitory effects of miR-211-5p on TNBC cell proliferation and metastasis.

Conclusions: These findings collectively demonstrate a tumour suppressor role of miR-211-5p in TNBC progression by targeting SETBP1, suggesting that miR-211-5p could serve as a potential prognostic biomarker and therapeutic target for TNBC.

Citing Articles

SET-binding protein 1 (SETBP1) suppresses cell proliferation in estrogen receptor-positive breast cancer.

Ando Y, Masuda T, Hayashi N, Kosai K, Shibuta S, Ono Y Breast Cancer. 2025; .

PMID: 39979691 DOI: 10.1007/s12282-025-01667-w.

Identification and characterization of host miRNAs that target the mouse mammary tumour virus (MMTV) genome.

Gull B, Ahmad W, Baby J, Panicker N, Khader T, Rizvi T Open Biol. 2024; 14(12):240203.

PMID: 39657819 PMC: 11631425. DOI: 10.1098/rsob.240203.

Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer.

Haque M, Shyanti R, Mishra M Front Oncol. 2024; 14:1431418.

PMID: 39450256 PMC: 11499239. DOI: 10.3389/fonc.2024.1431418.

The dual role of sirtuins in cancer: biological functions and implications.

Yu L, Li Y, Song S, Zhang Y, Wang Y, Wang H Front Oncol. 2024; 14:1384928.

PMID: 38947884 PMC: 11211395. DOI: 10.3389/fonc.2024.1384928.

SETBP1 activation upon MDM4-enhanced ubiquitination of NR3C1 triggers dissemination of colorectal cancer cells.

Zhai P, Zhang H, Li Q, Hu Z, Zhang H, Yang M Clin Exp Metastasis. 2024; 41(5):747-764.

PMID: 38796806 DOI: 10.1007/s10585-024-10294-2.

References

Stieglitz E, Troup C, Gelston L, Haliburton J, Chow E, Yu K . Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 2014; 125(3):516-24. PMC: 4296011. DOI: 10.1182/blood-2014-09-601690. View

Kanaan Z, Roberts H, Eichenberger M, Billeter A, Ocheretner G, Pan J . A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013; 258(3):400-8. DOI: 10.1097/SLA.0b013e3182a15bcc. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

van Schooneveld E, Wouters M, Van der Auwera I, Peeters D, Wildiers H, van Dam P . Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012; 14(1):R34. PMC: 3496152. DOI: 10.1186/bcr3127. View

Kim B, Kang S, Han H, Lee J, Kim J, Lee S . Transcriptome-wide analysis of compression-induced microRNA expression alteration in breast cancer for mining therapeutic targets. Oncotarget. 2016; 7(19):27468-78. PMC: 5053664. DOI: 10.18632/oncotarget.8322. View

Boyle P . Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23 Suppl 6:vi7-12. DOI: 10.1093/annonc/mds187. View

Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S . LNA-mediated microRNA silencing in non-human primates. Nature. 2008; 452(7189):896-9. DOI: 10.1038/nature06783. View

Kwilas A, Ardiani A, Gameiro S, Richards J, Hall A, Hodge J . Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin. Oncotarget. 2016; 7(17):23498-511. PMC: 5029642. DOI: 10.18632/oncotarget.8274. View

Woolston C . Breast cancer. Nature. 2015; 527(7578):S101. DOI: 10.1038/527S101a. View

10.

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

11.

Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, Chaplin D . Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102(11):1555-77. PMC: 2883160. DOI: 10.1038/sj.bjc.6605642. View

12.

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View

13.

Yates L, Norbury C, Gilbert R . The long and short of microRNA. Cell. 2013; 153(3):516-9. DOI: 10.1016/j.cell.2013.04.003. View

14.

Shin V, Siu J, Cheuk I, Ng E, Kwong A . Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 2015; 112(11):1751-9. PMC: 4647231. DOI: 10.1038/bjc.2015.143. View

15.

Zheng G, Du L, Yang X, Zhang X, Wang L, Yang Y . Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br J Cancer. 2014; 111(10):1985-92. PMC: 4229633. DOI: 10.1038/bjc.2014.489. View

16.

Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M . Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013; 45(8):937-41. DOI: 10.1038/ng.2698. View

17.

Yaffe M, Jong R . Adjunctive ultrasonography in breast cancer screening. Lancet. 2015; 387(10016):313-314. DOI: 10.1016/S0140-6736(15)00787-4. View

18.

Prasadam I, Batra J, Perry S, Gu W, Crawford R, Xiao Y . Systematic Identification, Characterization and Target Gene Analysis of microRNAs Involved in Osteoarthritis Subchondral Bone Pathogenesis. Calcif Tissue Int. 2016; 99(1):43-55. DOI: 10.1007/s00223-016-0125-7. View

19.

Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A . Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2012; 45(1):18-24. PMC: 3588142. DOI: 10.1038/ng.2495. View

20.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View